Shuttle Pharmaceuticals Holdings (SHPH) Non-Current Deferred Tax Liability (2022 - 2025)
Shuttle Pharmaceuticals Holdings (SHPH) posted quarterly Non-Current Deferred Tax Liability of $2485.0 for Q4 2025, up 25.82% year-over-year from $1975.0 in Q4 2024, and up 25.82% quarter-over-quarter from $1975.0 in Q4 2024.
Shuttle Pharmaceuticals Holdings (SHPH) Non-Current Deferred Tax Liability (2022 - 2025) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $2485.0 for Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability rose 25.82% year-over-year to $2485.0; the TTM figure through Dec 2025 stood at $2485.0 (up 25.82% YoY), while the FY2025 annual figure was $2485.0, up 25.82% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at $2485.0, up from $1975.0 in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $3.5 million in Q4 2023, with the low at $1975.0 in Q4 2024.
- The 4-year median for Non-Current Deferred Tax Liability is $54699.5 (2022), against an average of $907214.8.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability surged 3190.01% in 2023, then plunged 99.94% in 2024.
- Shuttle Pharmaceuticals Holdings' Non-Current Deferred Tax Liability stood at $106914.0 in 2022, then soared by 3190.01% to $3.5 million in 2023, then slumped by 99.94% to $1975.0 in 2024, then climbed by 25.82% to $2485.0 in 2025.
- Business Quant data shows SHPH's Non-Current Deferred Tax Liability at $2485.0 in Q4 2025, $1975.0 in Q4 2024, and $3.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Shuttle Pharmaceuticals Holdings | 1.91 Mn | 1.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,485.00 |
| Dec 31, 2025 | 2,485.00 |
| Dec 31, 2024 | 1,975.00 |
| Dec 31, 2024 | 1,975.00 |
| Dec 31, 2023 | 3.52 Mn |
| Dec 31, 2023 | 3.52 Mn |
| Dec 31, 2022 | 106,914.00 |
| Dec 31, 2022 | 106,914.00 |